全文获取类型
收费全文 | 3717篇 |
免费 | 237篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 30篇 |
儿科学 | 168篇 |
妇产科学 | 84篇 |
基础医学 | 483篇 |
口腔科学 | 41篇 |
临床医学 | 730篇 |
内科学 | 609篇 |
皮肤病学 | 25篇 |
神经病学 | 330篇 |
特种医学 | 58篇 |
外科学 | 288篇 |
综合类 | 32篇 |
一般理论 | 3篇 |
预防医学 | 497篇 |
眼科学 | 36篇 |
药学 | 242篇 |
中国医学 | 3篇 |
肿瘤学 | 300篇 |
出版年
2023年 | 13篇 |
2022年 | 21篇 |
2021年 | 52篇 |
2020年 | 44篇 |
2019年 | 76篇 |
2018年 | 82篇 |
2017年 | 48篇 |
2016年 | 67篇 |
2015年 | 66篇 |
2014年 | 103篇 |
2013年 | 183篇 |
2012年 | 231篇 |
2011年 | 248篇 |
2010年 | 147篇 |
2009年 | 100篇 |
2008年 | 215篇 |
2007年 | 210篇 |
2006年 | 228篇 |
2005年 | 253篇 |
2004年 | 250篇 |
2003年 | 234篇 |
2002年 | 240篇 |
2001年 | 34篇 |
2000年 | 25篇 |
1999年 | 41篇 |
1998年 | 39篇 |
1997年 | 51篇 |
1996年 | 33篇 |
1995年 | 41篇 |
1994年 | 28篇 |
1993年 | 28篇 |
1992年 | 23篇 |
1991年 | 26篇 |
1990年 | 26篇 |
1989年 | 23篇 |
1988年 | 23篇 |
1986年 | 13篇 |
1985年 | 14篇 |
1984年 | 20篇 |
1983年 | 25篇 |
1982年 | 24篇 |
1981年 | 43篇 |
1980年 | 23篇 |
1978年 | 19篇 |
1977年 | 21篇 |
1976年 | 19篇 |
1975年 | 14篇 |
1974年 | 17篇 |
1973年 | 14篇 |
1972年 | 16篇 |
排序方式: 共有3959条查询结果,搜索用时 15 毫秒
1.
Will Kaufman Augustine S Chavez Betty Skipper Arthur Kaufman 《International journal for equity in health》2006,5(1):6-5
Background
A public hospital in New Mexico required collection of 50% of estimated costs prior to elective surgeries for self-pay patients. This study assesses the impact of this policy on access to elective surgical procedures. 相似文献2.
Teenage pregnancy is a well-documented problem in the United States, with approximately 890,000 teenage pregnancies occurring each year. Although teen pregnancy rates have declined since 1991, rates remain higher than the mid-1970s and are fourfold those of European countries. Substantial morbidity and social problems result from these pregnancies, affecting the mother, her children, other family members, and society. Multiple educational approaches have been used, with few demonstrating significant reductions in teen pregnancy. School-based programs have been diverse and multifaceted. Recently, programs with a comprehensive approach have shown potential for success. In this article, characteristics and elements of promising school-based programs are identified and discussed. It is imperative that school nurses play an active role in developing and implementing prevention programs that incorporate rigorous evaluation. As health educators, school nurses are in a prime position to implement and evaluate the effectiveness of teen pregnancy prevention programs. 相似文献
3.
4.
5.
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. 总被引:11,自引:0,他引:11
Fairooz F Kabbinavar Joseph Schulz Michael McCleod Taral Patel John T Hamm J Randolph Hecht Robert Mass Brent Perrou Betty Nelson William F Novotny 《Journal of clinical oncology》2005,23(16):3697-3705
PURPOSE: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC). This randomized, phase II trial compared bevacizumab plus fluorouracil and leucovorin (FU/LV) versus placebo plus FU/LV as first-line therapy in patients considered nonoptimal candidates for first-line irinotecan. PATIENTS AND METHODS: Patients had metastatic CRC and one of the following characteristics: age > or = 65 years, Eastern Cooperative Oncology Group performance status 1 or 2, serum albumin < or = 3.5 g/dL, or prior abdominal/pelvic radiotherapy. Patients were randomly assigned to FU/LV/placebo (n = 105) or FU/LV/bevacizumab (n = 104). The primary end point was overall survival. Secondary end points were progression-free survival, response rate, response duration, and quality of life. Safety was also assessed. RESULTS: Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16). Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo); hazard ratio was 0.50; P = .0002. Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055); duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo); hazard ratio was 0.42; P = .088. Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%) but was controlled with oral medication and did not cause study drug discontinuation. CONCLUSION: Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival. 相似文献
6.
7.
8.
9.
A Holte 《Maturitas》1992,14(2):127-141
As a continuation of a cross-sectional study in 1981 involving a representative sample of 1886 women between 45 and 55 years of age, 200 pre-menopausal subjects were selected randomly to take part in a follow-up study. Eighty-seven single measures covering 26 areas of health complaints which have been associated with the menopause in medical textbooks were investigated. A tentative method for relating health complaints at several time points to menopausal status is proposed. A significant number of women reported an increase in vasomotor complaints, vaginal dryness, heart palpitations and social dysfunction following the menopause, although many reported no change or even a reduction in these complaints. On the other hand, a decrease in headache and breast tenderness was noted. No significant differences were observed between the numbers of women reporting an increase or a decrease respectively on any of the other 69 measures (20 complaints), which included anxiety, depression and irritability. Further analyses indicated that the increase in social dysfunction was caused by hot flushes and sweating. This paper raises a number of issues regarding the methodology of longitudinal studies. 相似文献
10.
OBJECTIVES: This report presents final 2001 data on the 10 leading causes of death in the United States by age, race, sex, and Hispanic origin. Leading causes of infant, neonatal, and postneonatal death are also presented. This report supplements the annual report of final mortality statistics. METHODS: Data in this report are based on information from all death certificates filed in the 50 States and the District of Columbia in 2001. Causes of death classified by the International Classification of Diseases, Tenth Revision are ranked according to the number of deaths assigned to rankable causes. RESULTS: In 2001, the 10 leading causes of death were (in rank order) Diseases of heart; Malignant neoplasms; Cerebrovascular diseases; Chronic lower respiratory diseases; Accidents (unintentional injuries); Diabetes mellitus; Influenza and pneumonia; Alzheimer's disease; Nephritis, nephrotic syndrome and nephrosis; and Septicemia and accounted for nearly 80 percent of all deaths occurring in the United States. Differences in the rankings are evident by age, sex, race, and Hispanic origin. Leading causes of infant death for 2001 were (in rank order) Congenital malformations, deformations and chromosomal abnormalities; Disorders related to short gestation and low birth weight, not elsewhere classified; Sudden infant death syndrome; Newborn affected by maternal complications of pregnancy; Newborn affected by complications of placenta, cord and membranes; Respiratory distress of newborn; Accidents (unintentional injuries); Bacterial sepsis of newborn; Diseases of the circulatory system; and Intrauterine hypoxia and birth asphyxia. Important variation in the leading causes of infant death is noted for the neonatal and postneonatal periods. 相似文献